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CHAPTER ONE
INTRODUCTION
Protection of Self from a wide range of pathogens is controlled by immunity, divided into
two subgroups: innate and adaptive 1. One of the driving factors behind innate immunity is the
early response of inflammation, which is induced by either microbial infection or tissue damage.
An inflammatory response is often beneficial in controlling infections and protecting an
individual from foreign invaders. When uncontrolled, a hyperinflammatory response can lead to
a plethora of disorders, including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and
Rheumatoid Arthritis (RA) among many others 2. Understanding the factors that cause this
uncontrolled inflammation has been a popular topic within research, as further understanding can
lead to pathogenic control and potential drug targets.
Another topic within the field of biology that has gained considerable prominence in the
last few decades is autophagy, described as an intracellular degradative process responsible for
the degrading or recycling of cellular materials 3. The lysosome is the key organelle responsible
for this degradative process, and impairments of the lysosome can lead to numerous disorders 4.
Within the many avenues of autophagy, the ones involving extracellular vesicle (EV) secretion
have been of high interest due to cells being able to exchange materials from one to the other via
EVs 5. EVs have been found in association with multiple neurodegenerative disorders, including
the previously mentioned PD and AD 6.
The association between EV secretion and inflammation has been appreciated within the
last decade, and it is this relationship that has intrigued us as a lab. Caspase-1, an effector
1
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protease of the inflammasome complex that is formed upon a diverse range of signals, has been
shown to drive the secretion of a wide volume of proteins. Unlike the conventional ER- Golgi
secretory pathway, caspase-1 drives protein secretion via non-conventional methods, including
EVs 5. Hence, we have two very different biochemical processes—inflammation and protein
secretion via EVs—that have relevant roles within disease pathogenesis and amongst themselves.
Additionally, it is the cargo associated with EV-secretion that interests us a lab. Different cargo
can either exert biological functions on neighboring cells, or in association with EVs can
potentially represent biomarkers for various diseases.
The goals of this research consist of further elucidating the mechanisms behind these two
distinct biochemical pathways, and how the association between the two has further implications
to disease pathogenesis and progression. Using an imaging-based method that allows for
analyzation of EV populations on an individual EV level, we can further characterize EV groups
under different stimuli, look at different cargos associated with EVs, and label EVs via staining
for different markers—some well-established and some more recently appreciated. Through this
efficient and relatively fast approach, we can further elucidate the role EVs have within
inflammation and provide exciting new approaches for studying two very integral topics within
the field of Biology.

CHAPTER TWO
REVIEW OF THE LITERATURE
Inflammation
Inflammation, a general innate immune system response, is a crucial aspect of our early
host defense against numerous pathogens. A balance of inflammatory responses is essential to
maintain, as uncontrolled inflammatory responses drive the progression of many diseases. The
innate immune system is the first line of defense against foreign invaders. Pattern-Recognition
Receptors (PRRs) embedded on the surface of many cell types recognize specific microbial cell
patterns, categorized as Pattern Associated Molecular Patterns (PAMPs) and Damage Associated
Molecular Patterns (DAMPs) 7. The recognition of PAMPs and DAMPs by PRRs leads to
downstream inflammatory effects, most notably the formation of inflammasomes, and thus
partake in the process of eliminating foreign pathogen invaders.
Inflammasomes.
The inflammasome was first described in 2002, when a group discovered a multiprotein
complex consisting of NLRP1, ASC, and pro-inflammatory caspases that came together upon
inflammatory induction 8. At the time, it was known that caspase-1 cleaved pro-IL-1β
to its mature form, however the mechanism behind that wasn’t fully understood. Inflammasomes
are thus defined as multi-protein complexes made up of intracellular apoptosis-associated specklike protein containing a CARD (ASC) and a sensor NLR. Deemed as the sensors of innate
immunity, their formation and activation are processed as a response to infectious ‘attacks’,
3
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presenting themselves to cell surface receptors as the aforementioned PAMPs and DAMPs
(12). Activation of caspase-1, a cysteine protease involved in cleaving pro-inflammatory
cytokines such as IL-1β and IL-18 to their mature forms, is promoted by NLR family members
such as NLRP1, NLRP3, and NLRC4 9,10. The assembly and activation of each respective
inflammasome is dependent on various environments and stimuli. The most well studied of all
inflammasomes, and the one that will be the focus of this research, is NLRP3.
Interleukin-1β (IL-1β).
Interleukin-1β is a potent pro-inflammatory cytokine, and the main cytokine that will be
focused on throughout this research. It has a beneficial role mediating a host’s response to many
infectious agents 8,9,11. IL-1β is produced and processed by cell lines of the monocytic lineage,
including but not limited to monocytes, macrophages, and dendritic cells. It is a 31 kDa sized
protein in its inactive pro-form, and is broken down into a 17 kDa sized protein in its mature
active form. Upon LPS stimulation, IL-1β mRNA levels are greatly amplified after only 15
minutes, and the pro-form of IL-1β accumulates in the cell until inflammasome activation takes
place 12. Many processes can be involved for IL-1β release from the cell, including exocytosis of
secretory lysosomes, shedding of plasma membrane microvesicles, etc.. Like many cytokines, it
does not contain a signal peptide, and is thus secreted from cells via the non-conventional
secretory pathway which will be discussed later on. This was first suggested by a group that
treated cells with brefeldin A (BFA). BFA causes the collapse of the TGN, which is integral for
conventional protein secretion. Upon inflammatory stimulation, IL-1β was still released from
cells, thus suggesting an alternative route for release 13. Upon release, this cytokine has a role in
various cellular processes, including cellular differentiation, proliferation, and pyroptosis. IL-1β
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released from inflammatory-induced cells is one the indicators we will use to confirm NLRP3
inflammasome activation.
NLRP3 Inflammasome.
NLRP3 requires two steps for its activation and downstream effects: a priming first signal
and a secondary signal. The priming signal, or signal 1, is provided via microbial agents, such as
lipopolysaccharide (LPS), or endogenous cytokines, like IL-1β, which drive the activation of
transcription factor NF-KB 7. The activation of NF-KB leads to the upregulation of NLRP3, as
well as pro-inflammatory cytokines such as IL-1β and IL-18. The activation signal, or signal 2, is
caused by a plethora of agents, including ATP, monosodium urate, β-glucans, nigericin, and
other components like RNA viruses 5. ATP is often the agent we use to induce this activation
signal. A well-established DAMP, exogenous ATP is often hydrolyzed by endonucleases 14.
However, upon significant cellular damage and extracellular release, the levels of extracellular
ATP are far greater than what can be hydrolyzed. Thus, ATP can be recognized by macrophages
as a danger signal, and aids in inflammasome activation. P2X7 is a channel present on many cell
types, including macrophages, and ATP interacts with P2X7 by binding to it, leading to channel
dilation. This dilation also drives increased ROS within the cell, which also further drives
NLRP3 inflammasome activation 7. The NLRP3 protein itself is composed of three parts: an
amino terminal pyrin domain (PYD), a central nucleotide-binding and oligomerization domain
(NOD), and C-terminal leucine rich domain (LRR). It is the pyrin domain of NLRP3 that
interacts with the pyrin domain of ASC upon inflammasome activation 15. Once associated with
NLRP3, ASC recruits caspase-1 to the complex, thus forming the NLRP3 inflammasome. Upon
proximity, caspase-1 auto-cleaves itself to its active form, and then proceeds to cleave pro-
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inflammatory cytokines. This leads to the downstream effects of NLRP3 inflammasome
activation. A simplified version of this process is illustrated in Figure 1 below.

Figure 1. Simplified NLRP3 Inflammasome Activation (7). A priming signal, such as LPS,
interacts with surface PRR, such as TLR7, which leads to activation of NF-KB and the
upregulation of pro-inflammatory cytokines such as pro-IL-1β and pro-IL-18. These proinflammatory cytokines accumulate in the cytoplasm, reaching a max upregulation about 4 hours
after LPS stimulation. A secondary signal, either in the form of ATP, monosodium urate,
nigericin, etc.. causes the NLRP3 inflammasome to form, leading to pro-caspase-1 autocleavage
to it’s mature caspase-1 form, which then proceeds to cleave pro-inflammatory cytokines into
their mature forms, for eventual release from the cell and subsequent inflammatory cascade.
The NLRP3 inflammasome has been implicated in numerous disorders. In
Alzheimer’s, Aβ aggregates have been shown to activate NLRP3-ASC inflammasome, which
further amplifies amyloid pathology in vivo 16. Specifically, Aβ acts as the secondary activation
signal, similar to ATP. Additionally, Tau has also been shown to activate the NLRP3
inflammasome in a prion-like fashion, and ASC deficiency in mice caused an inhibition of this
exogenously seeded Tau pathology. Epstein-Barr virus (EBV), while usually presenting itself
asymptomatically in most patients, is an oncogenic virus responsible for many cancers upon
reactivation later in life, and its reactivation from its latent state has been attributed to excessive
NLRP3 inflammasome activation 17. In the same study that described how Aβ can activate the
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NLRP3 inflammasome, they also noted that ASC specks are released from inflamed microglial
cells, with the potential to propagate inflammation.
Apoptosis-Associated Speck-Like Protein Containing a CARD (ASC).
ASC is a 22 kDa protein which was first identified as having a caspase-recruiting
domain. This protein acts as the bridge between NLRP3 and caspase-1. ASC polymers
themselves are what bring pro-caspase-1's into close proximity with each other in the
inflammasome complex, which thus mediates the previously mentioned auto-cleavage to active
caspase-1 18. Characteristic speck formation of ASC are strong indicators of inflammasome
activation. Independent of the effects of ASC in the context of an inflammasome, ASC is also
released outside phagocytic cells into the cytosol. In the cytosol, ASC can still be visualized as
specks, and these specks have been reported to have prion-like properties and can promote
inflammation themselves (12) 18. To understand the potential effects of ASC as a prion-like
protein, a better understanding of prions needs to take place.
Prion Proteins.
Prions are cell surface proteins expressed on numerous cell types in various organs,
specifically those relating to the peripheral and central nervous systems 19,20. Their presence on
cell surfaces increases as brain development progresses in humans. However, there is some
debate regarding the presence of prion proteins in older individuals. In post-mortem individuals,
there is a decrease in prion proteins in older individuals, while in mice there is an increase 21.
Regardless, the exact function of prion proteins is not fully understood. KO PrPc in mice
prevented progression of scrapie transmission, a prion disease, which is unsurprising as the
process is dependent on prion proteins. However, no other phenotypes were observed, which is
surprising in itself as the sequence and structure of prion proteins are well conserved in many
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animal species. It has been suggested that PrPc is associated with ER stress, as PrPc is
overexpressed upon addition of agents that induce ER stress. ER stress is caused by an
accumulation of unfolded or misfolded proteins, which increases expression of chaperone
proteins that aid in folding, and inhibits protein synthesis to give cells time to correct misfolded
or unfolded proteins. The main area of focus regarding prion proteins is their role in disease,
specifically neurodegenerative disorders. PrP is able to conformationally change from its cellular
state, PrPc, to its insoluble isoform PrPSc, which is resistant to proteinase K degredation22.
Misfolded prions can then transfer from cell to cell, thus inducing conformational changes on
other normally folded prion proteins, thus aiding in disease propagation. As our lab studies
neurodegenerative disorders, it is important to further understand inflammasome proteins, like
ASC, which have the potential to act in a prion-like manner. Additionally, we also study
processes of protein secretion from cells. Cells that undergo inflammasome activation are
responsible for an increase in protein secretion, and EV release as well. To further understand the
potential role ASC has as it is released from cells, we need to first delve into the different
avenues of protein secretion.
Autophagy and Protein Secretion
Autophagy is a self-degradative process that is important for recycling cellular material,
responding to nutrient requirements and stressors, removing damaged organelles, and removing
aggregated or misfolded proteins 23,24. Overall, the process begins with an autophagosome (likely
derived from the lipid bilayer of the ER) consuming cellular cargo, be it organelles, proteins,
protein aggregates, etc.. Upon engulfment, the autophagophore becomes a double membraned
autophagosome. This autophagosome later fuses with the lysosome, which degrades the
consumed cargo. Proteases within the lysosome break down the products upon fusion, where
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they can later on be reused or discarded from the cell. An illustration of the main types of
autophagy are shown in Figure 2 below. The autophagy-lysosome system is vital for controlling
infection and eventual immunity, in terms of breakdown of foreign microbial agents and
antigenic presentation to immune cells. Beyond a relationship between autophagy and
immunology that can be appreciated, autophagy is also crucial for protein secretion from the cell.
Additionally, it has been suggested that EVs are cleared from cells via the autophagy-lysosome
pathway, and thus a clear understanding of degradation and protein secretion are of high
importance to better understand EVs 25.
Classical/Conventional Secretory Pathways.
Conventionally secreted proteins are categorized and labeled by a signal peptide on the
N-terminal end, which directs the proteins from the ER to the Golgi apparatus 14. From there,
proteins are moved to the trans-Golgi network (TGN), and eventually to the plasma
membrane 11. Regulatory proteins are responsible for control throughout this process. Up until
the last two decades, this classical protein secretion pathway has been thought of as the standard
for protein secretion.
Non-Classical/Non-Conventional Secretory Pathways.
Proteins secreted from cells using pathways that don’t involve ER-to-Golgi transport are
categorized in the non-classical/non-conventional secretory pathway. There are two main
subgroups of non-conventional protein secretion: those that do not contain the aforementioned
signal peptide on the N-terminal end, and those that do have a signal peptide but bypass the
Golgi 11. Most of the proteins that are secreted via this pathway aren‘t done so under normal
cellular conditions. Rather, their secretion is often induced by cellular stress, mechanical stress,
and inflammation. Activation of P2X7 channels, which as mentioned previously interact with
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extracellular ATP and drive NLRP3 inflammasome activation, are largely responsible for
changing cellular morphology. It is under these morphological changes that there is an increase
of proteins trafficked to the membrane to be released via vesicles 14. Many cytokines are released
in this pathway, as they do not contain signal peptides 11.
Extracellular Vesicles
As an overall generalized term, EVs refer to membrane bound vesicles containing various
molecules26, further categorized by their size, origin, release pathways, and environments 25.
Once thought to be cell debris that have no additional value or function upon release 27, EVs are
now appreciated as having an important role in many biological processes, including transfer of
proteins and RNA from cell to cell, thus suggesting a role in intercellular communication 26. EVs
can be broken down into the following groups: apoptotic bodies, microvesicles, and exosomes,
as illustrated in Figure 2 below 28,29.

Figure 2. Breakdown of EV Formation (28). The three main categories of EVs are illustrated,
showing the origin of their formation. Apoptotic bodies are released from dying cells. MVs are
released from budding of the plasma membrane. Lastly, exosomes are released from endocytic
vesicles fusing with the plasma membrane, releasing their contents.
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Apoptotic Bodies.
Apoptotic bodies were the first categorized group of EVs, and have been described as
EVs released from cells undergoing apoptosis 28. An appreciation for EVs released from healthy
cells has been well established in the field, however apoptotic bodies have been mostly
overlooked throughout the growing understanding of EVs in the field. Apoptotic bodies are
usually within the range of 1-5 µm, although some have also been mentioned to be smaller than
1 µm. Upon apoptosis, dead cells are either cleared by phagocytes as whole cells, or as
fragments—which include apoptotic bodies 30. Some phagocytes can’t consume the full dead cell
due to sheer size, which places an even bigger importance on cells abilities to release apoptotic
bodies during apoptosis. Apoptotic bodies have also been shown to have a role in recruiting
phagocytes to the site of apoptosis for clearance using ’find me’ signals, including release of
factors such as ATP, which as mentioned before can be recognized by macrophages as a danger
signal and elicit NLRP3 activation. This clearance under normal, healthy physiological
conditions is paramount to maintaining homeostasis, and individuals that aren’t able to clear
apoptotic cells have been linked to inflammatory diseases and autoimmunity. Apoptotic bodies
can also assist in antigen presentation via MHC class II, and thus have the ability to stimulate
CD4+ T cells 31.
Microvesicles.
Microvesicles, the next subgroup of EVs, are usually between 100 nm and 1 µm in size.
They express phosphatidylserine (PS) on their surface, as confirmed via annexin staining,
although there have also been PS negative MVs 3233. They characteristically are formed by
outward budding of a cell’s plasma membrane, so their content is primarily composed of
cytosolic and membrane associated proteins. They also have been suggested to require actin and
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microtubules for their release, and such components can also be associated with their release.
Uptake of MVs by recipient cells has been acknowledged as an energy dependent process, as a
decrease in uptake has been observed under conditions with lower temperatures.
Exosomes.
Exosomes are the last subgroup of EVs, and while there has been some debate regarding
the similarities between exosomes and MVs, they are a separate class of themselves and do have
distinct differences. The defining difference between exosomes and MVs is that while MVs bud
outwards from the cytosol to the PM, exosomes are secreted from multivesicular bodies, or
MVBs, which are late endosomes26,29,32–34. As mentioned previously discussing autophagy,
endosomal structures are formed containing cargo that can later fuse with the lysosome, and thus
get degraded. In this case, there is no fusion with the lysosome: instead, late endosome fuses
with the PM and releases its content to the extracellular space. While the exact details of what
deems MVBs for extracellular release vs fusion with the lysosome for degradation is still up for
debate, it has been shown that in nutrient starved cells, MVBs are re-routed for degradation as
opposed to extracellular release, so the cellular environment plays a role in exocytosis.
Exosomes are usually smaller than MVs, and are between 40-150 nm in size.
Tetraspanins.
Due to the origin and distribution of various classes of EVs, it doesn’t come as a surprise
that different classes have their own distinct markers. However, there are pan-EV markers that
span all EVs. Tetraspanins are a protein superfamily that act as transmembrane proteins, with
large extracellular loop (LEL) that acts as its most antigenic feature 35. Of the tetraspanins, the
three most commonly used to identify EVs are CD9, CD63, and CD81. A group in 2016
subjected EVs released from human primary monocyte derived dendritic cells to various
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ultracentrifugation (UC) techniques: 2000g, 10000g, and 100,000g 36. The 100k UC technique is
accepted to yield a pellet of mostly exosomes, ranging in size from 50-150nm, which is what
they saw. The 2k technique yielded mostly larger sized EVs (>200nm), while 10k technique
yielded EVs closer in distribution to the 100k. When they performed a Western Blot of proteins
from the different centrifugations, they noted that the 100k pellet had strong bands for all
three tetraspanins, however CD9 and CD63 were also present in the 2k and 10k pellets as well.
There was some hope that tetraspanins could become a specific exosome EV marker, however
due to these proteins being expressed on the cell membrane, they can also very easily be
incorporated into other subgroups of EVs that originate from cell budding 37. A breakdown
of tetraspanin distribution along the cell membrane is shown in the figure below.

Figure 3. Representation of Tetraspanin Distribution along PM (38). Localization and how
tetraspanins span the plasma membrane are clearly illustrated, as well as other membrane
markers that can be incorporated into EVs prior to release from cell. Additionally, the
importance of these markers for fusion with target cells is also shown under section C.
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Other EV Makers.
Digressing from pan-markers, there are certain proteins that are associated with certain
EV subgroups based on their origin and biogenesis. Exosomes, for example, have proteins
associated with endosomal sorting complex required for transport, or ESCRT, which include
ALG-2 interacting protein X (ALIX) and tumor susceptibility gene 101 (TSG101)39. ESCRT
proteins help with sorting ubiquitinated proteins to their designated MVBs, and also assist with
exocytosis 40. A proteomic analysis of different markers for different EVs sorted by sizes and
various centrifugation techniques is visualized in the figure below.

Figure 4. EV Subgroup-Specific Markers (41). As illustrated, tetraspanins (including CD9,
CD63, and CD81) are present in multiple EV subgroups, however CD81 is somewhat more
concentrated in smaller EVs. Additional markers present on multiple EVs are MHC-I/II, Heat
Shock Proteins, Annexin, etc..
Glycobiology and Lectins.
Like EV studies themselves, carbohydrate function in the context of cellular
communication was not fully appreciated until the last few decades. Bound to lipids and proteins
as glycans, carbohydrate subgroups are now accepted to have important roles as information
carriers within cellular trafficking 42. It is also appreciated that glycoconjugates are involved in
EV biogenesis and play a role in their recognition by target cells and their uptake. Additionally,
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there are alterations to glycome composition of cells in various disease states, which is another
reason why a precise way to label and analyze EVs based on their glycan composition can be
hugely beneficial as disease biomarkers. Nearly half of all proteins are glycosylated, and
individual proteins can have many different glycosylation sites. The question then becomes: how
do we best analyze and label these carbohydrate structures? The answer to this rests within
Lectins, which are carbohydrate binding proteins. Lectins recognize and bind to different glycan
epitopes on various structures. There are numerous types of lectins, and different lectins will
bind to certain cell types under certain conditions depending on their glycan composition. EVs
themselves have a defined glycan distribution, and thus utilizing lectins as an EV marker tool has
been of great excitement within the field and our lab.
Galectins are a subgroup of lectins which specifically bind β-galactosyl containing
glycoconjugates, and they are the most highly expressed subgroup of lectins in all organisms 43.
Studies have shown that Gal-3, which binds to sugars present on the exterior portion of the PM
or the internal portion of intracellular vesicles, has been used as a tool to distinguish ruptured
vesicles 44,45.

CHAPTER THREE
MATERIALS AND METHODS
Cell Culture.
The HEK293T and the THP-1 immortalized cell-lines were purchased from the American Type
Culture Collection (ATCC). HEK293T and THP-1 cells were cultured at 37°C and 5% CO2 in
Dulbecco's modified Eagle's Medium (DMEM) containing phenol red (Invitrogen) or Roswell
Park Memorial Institute (RPMI) 1640, supplemented with the 10% fetal bovine serum (FBS)
(Hyclone), 10ug/ml ciprofloxacin hydrochloride, 100IU/ml penicillin, and 100ug/ml
streptomycin. To generate EV depleted media, FBS was diluted 4x in DMEM or RPMI and was
ultracentrifuged for 18 hours, depending on the intended cell type. Afterwards the supernatant
was collected and added to either DMEM or RPMI and supplemented with antibiotics.
Differentiation.
THP-1 cells were differentiated into monocyte-derived macrophages by the addition of X
phorbol myristate acetate (PMA) (Sigma) at a 1:10000 dilution for 24-48 hours, followed up by
RPMI media change sans PMA for 24-48 hours.
Stable Expression of S15 mCherry Construct.
HEK293Tand THP-1 cells were transduced to stably express S15-mCherry using the lentiviral
vector (pLVX) backbone containing a CMV promoter to drive the expression of S15-mCherry.
Lentiviral particles were generated by polyethylenimine (PEI) transfection of HEK293T cells.
The transfection was performed overnight with equal DNA concentrations of VSV-g, ΔNRF or
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psPax2, and pLVX-CMV-S15-mCherry plasmid. The next morning the cell medium was
changed. The cultured medium from the transfected HEK293T cells was collected 48 hours later
and filtered through a 0.45µm syringe filter (Millipore). The purified medium was directly added
to THP-1 cells. 72 hours later the cells were selected for expression of our S15-mCherry
construct by supplementing DMEM or RPMI 1640 with 5ug/ml puromycin (Hyclone).
Generation of GFP Fusion Protein Constructs.
Expression plasmids containing HIV-1 proteins TAT, VPR, and NEF were all generated by PCR
based cloning and restriction enzyme strategies. Primers against TAT, VPR, and NEF proteins
were created and either first inserted into the pEGFP-N1 plasmid to create N-terminal GFP
fusion constructs of TAT and NEF followed by subcloning into the lentiviral (pLVX) plasmid or
directly inserted in pLVX C1-GFP in the case of VPR.
Transfection of HIV-1 GFP Constructs.
HEK293T cells were transfected at approximately 60 percent confluency using Polyethylenimine
(PEI), and either pLVX TAT-GFP, GFP-VPR, or NEF-GFP plasmids overnight. The media was
changed after overnight transfection and collected 48 hours later. EVs in the cultured media was
concentrated via ultracentrifugation as described below.
Immunofluorescence Staining.
In order to adhere EVs to coverslips, either 80µl of resuspended concentrated EV was added to
420µl of PBS totaling 500µl or, for unconcentrated EVs, 500µl of supernatant cultured media
was added into the well of 24-well plate containing a glass coverslip (Fischerbrand microscope
cover slides, 12-545-J, 22X60-1). Coverslips were initially held in a 50ml conical in 70% ethanol
and were added to individual wells of a tissue culture, 24-well plate and subsequently washed
with PBS three times. The final round of PBS was left in the well and aspirated immediately
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before continuing. The contents of the 24-well plate were spinoculated by centrifugation at 13°C
for 2 hours at 1200g onto the coverslips and subsequently fixed in a solution of 0.1 M PIPES
containing 3.7% formaldehyde (Polysciences) for 10 minutes and washed 3 times with PBS. The
coverslips were permeabilized with a 0.1% solution of saponin in block solution composed of
500mL of PBS supplemented with 10% normal donkey serum (NDS), and 0.01% NaN3 for 5
minutes. After washing 3 times, the coverslips were incubated with rabbit anti-LAMP1
antibodies (Abcam #24170) or rabbit anti-TSG101 (Abcam ab125011) and either mouse antiCD9 (BD Pharmingen #555370), mouse anti-CD63 (BD Pharmingen #5556019), or mouse antiCD81 (BD Pharmingen #555675), in the previously stated block solution for 1 hour at room
temperature. All primary antibodies were used at 1:1000. In experiments using lectins, biotin
conjugated lectins (Vector Laboratories) were used at a working concentration of 5mg/mL in
place of primary antibodies for 1.5 hours at room temperature. Afterwards the coverslips were
washed with PBS and subsequently incubated with secondary antibodies of conjugated donkey
anti-mouse 488 (Jackson ImmunoResearch Laboratories, Inc.) and donkey anti-rabbit 647
(Jackson ImmunoResearch Laboratories, Inc.) at a concentration of 1:400 for 30 minutes at room
temperature diluted in PBS block solution and washed with PBS. Additionally, FITC conjugated
streptavidin (SAV) (Jackson ImmunoResearch Laboratories, Inc. 016-600-084) at 1:1000 was
added for 1 hour at room temperature, diluted in PBS block, and washed with PBS. Afterwards,
coverslips were fixed and mounted (Electron Microscopy Sciences, Fluoro-gel with Tris buffer,
#17985-11) onto slides (Globe Scientific Inc., Diamond White Glass 25x75x1mm, .5 gloss,
#1380-30). In experiments using poly-L-lysine coated coverslips, coverslips were coated by
adding 500µl of 0.1% of poly-L-Lysine solution (Sigma Aldrich) to the well and incubated at
37oC for 1 hour. Following incubation, the coverslips were washed 3x with PBS before
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continuing with spinoculations.
PKH Dye Labeling of EVs.
EVs from saliva and plasma were isolated as previously described in the collection, preparation
and processing methodology section. Similarly, wildtype or S15Ch 293Ts pelleted EVs were
concentrated via previously described purification of extracellular vesicle methodology using
starting volumes that filled SW28, Beckman Coulter polycarbonate centrifuge tubes (#344058).
Afterwards, 293T concentrated EVs were directly resuspended in 100µl of PBS, while saliva and
plasma EVs were resuspended in 500µl of PBS overnight on the orbital shake 4oC as described
previously. To prepare the EVs for staining, 50µl of either concentrated WT or S15Ch 293T EVs
were added to 950µl of Diluent C (Phanos Technologies) while 200µl of concentrated saliva EVs
or 500µl of plasma EVs were added to 800µl or 500µl of Diluent C, respectively. Next, a master
mix of 0.2µl or 0.4µl of PKH26 or PKH67 (Phanos Technologies) was added to 1ml of Diluent
C (Phanos Technologies) per sample to create a final concentration of 200nM or 400nM,
respectively. A 200nM PKH67 dye master mix was used for both saliva and plasma EVs. 1ml of
the PKH dye master mix was added to the 1ml EVs and Diluent C mixture and was gently
pipetted for 30 seconds, followed by being shaken at room temperate on an orbital shaker at
100rpm, for 5 minutes. Afterwards, the reaction was quenched by adding 2ml of 10% BSA
(Sigma-Aldrich, #05470) resuspended in PBS. 4.5ml of serum free DMEM was added to the
quenched reaction to a total volume of 8.5ml. Next, to minimize turbulence, the 8.5ml mixture
was very gently floated on-top of a 1.5ml .971M sucrose (Sigma-Aldrich, #S9378) cushion in a
Beckman Coulter polycarbonate centrifuge tube (#349622) and topped off with serum free
DMEM. This was followed by centrifugation at 190,000g for 2 hours at 4oC via the SW41 TI
rotor to pellet the EVs while removing excess dye. The supernatant and the sucrose cushion were
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carefully aspirated, and the pellet was resuspended in 500µl of PBS by gentle pipetting. The
resuspended S15Ch or WT 293T pellet was used immediately or stored at -20oC for later use.
The resuspended saliva and plasma EVs were stored at -20oC until need and thawed at room
temperature. In preparation for imaging, 250µl of the WT or S15Ch resuspension was added to
250µl of PBS and spinoculated onto uncoated coverslips per condition. Conversely, 50µl of the
thawed plasma or saliva EVs were added to 450µl of PBS and spinoculated onto 0.1% Poly-LLysine (Sigma Aldrich) coated coverslips as described previously. EVs were then subjected to
immunofluorescence staining as described in immunofluorescence staining methodology section.
In Vitro NLRP3 Inflammasome Activation.
Differentiated THP-1 cells were plated in 6 well, 60mm, or 10cm plates and stimulated with the
indicated stimuli. Cells were primed with 10 ng/mL LPS (from E. coli 055:B5, Sigma-Aldrich)
for 4h followed by 5 mM ATP (Invivogen) for 3h.

CHAPTER FOUR
RESULTS
As shown in our recently published paper, we have developed a technique to allow for
evaluation of heterogenous EV populations on an individual level (46). This image-based
workflow aided by fluorescent microscopy is used to characterize EVs via Multiplexed Analysis
of Co-localization, or EV-MAC. With this technique, we are able to characterize EVs from
different cell types, as well as analyze differences in the distribution of various EV markers in
said populations. It is with this technique that we are able to more definitively analyze EV
populations under different inflammatory inductions, which will be described later on.
Initially, we had to demonstrate the effectiveness of EV-MAC in being able to elucidate
differences in EV populations containing different cargos. To do this, we used GFP-tagged
versions of various HIV-1 proteins, such as Tat, Vpr, and Nef. These proteins have been shown
as cargo associated with EVs released from HIV-1 infected cells 47. These constructs were
transfected into 293Ts, and media from the cells was collected after the allotted time. EVs were
spun onto coverslips, stained, and then visualized microscopically. Surfaces around the GFPtagged proteins were built as described previously, and to each surface we analyzed
colocalization with various EV markers such as CD9, CD63, CD81, and LAMP1, as well as
TSG101 which has been stated to be incorporated into EV membranes. The localization patterns
were quantified and graphed in Figure 5. As evident, different HIV-1 proteins released were
associated with different distributions of EV markers. These data support the sensitivity of our

21

22
technique and our ability to specifically quantify cargos associated with EVs released from cells,
as confirmed by colocalization with various EV markers.

Figure 5. EVs Associated with Different HIV-1 Proteins Have Different Distributions of
Pan-EV Markers (46). The degree of co-localization of (A) TAT-GFP, (B) GFP-VPR, and (C)
NEF-GFP EVs with tetraspanin markers, LAMP1 and TSG101. The data shown is the mean
value from three independent media preparations and coverslips in which pooled data from a
single coverslip was used to determine the mean co-localization percentages. Error bars show the
standard error of the mean.
Lectins bind to carbohydrates of different sugar linkages that are present on both
glycoproteins and glycolipids that make up EVs. Our interest progressed further to see if we can
use lectins to stain for these linkages, and thus be useful as additional EV markers. To confirm
which lectins would be the best EV marker, we examined the glycan composition associated
with our S15Ch+ EVs by staining with various biotinylated lectins under two conditions: normal,
and under conditions where lysosome acidification has been disrupted, such that EVs released
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from cells have altered composition48. Figure 6 shows the diversity in lectin distribution amongst
our S15Ch+ EVs, and how lectin composition is affected under various stimuli. This supports the
notion that some lectins could be used as comprehensive EV markers, and their distribution
would change accordingly with differing stimuli.

Figure 6. S15Ch+ EVs and Lectins Colocalize Under Normal and Lysosome-Inhibited
States (46). A) The cultured media from S15Ch 293Ts was incubated with the indicated
biotinylated lectins followed by Alexa 488 streptavidin to determine the glycan profile of EVs
under both DMSO Vehicle (DMSO) and 100nM Bafilomycin-A1 (BafA1) treated conditions. B)
Data shown is the mean percent co-localization summation of at least three independent media
preparations and coverslips. Significant differences between control and BafA1 treated samples
were determined via two-tailed T-test. * = p-value < .05, ** = p-value < .01, *** = p-value <
.001.Error bars show standard error of the mean.
So far, we have used pan EV markers such as tetraspanins to stain for EVs released from
cells, and have shown that some lectins bind highly to carbohydrate structures present on EVs of
certain cell types, with lectin distributions varying under different conditions. Our next aim was
to confirm the effectiveness of fluorescent membrane dyes in labeling EV populations. PKH
dyes are fluorescent lipophilic dyes, in which the aliphatic tail of the dye binds to exposed lipid
bilayers. This interaction is maintained by long term, strong noncovalent interactions 49.
Via lateral diffusion, entire cell membranes can be stained with this dye, thus making them very
useful in cell labeling. We collected EVs from 293Ts, concentrated them, and incubated them
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with PKH26 membrane dye using concentrations of 200nM and 400nM. Excess dye was
removed, and we proceeded to spinoculate EVs onto coverslips as previously mentioned, while
staining for CD81 and LAMP1. We also used the dye with our S15Ch+ EVs, and saw that while
50% of the PKH puncta were S15Ch+ positive, all the S15Ch+ EVs were positive for the dye.
This suggests that the dye is potentially staining additional EVs that our S15Ch+ construct isn’t
incorporated in, or at least to the strength that would be detected by our microscope. Results
from this experiment are shown in Figure 7 below. Worth noting is that non-EV associated
fluorescent structures have been noted to form, some much larger in size and some similar in size
to EVs. The dye forms micelles when not in the presence of structures to take up the dye. Hence,
there needs to be an appropriate dye-to-protein ratio when proceeding with PKH dye staining.
Additionally, it’s been shown that a sucrose gradient following ultracentrifugation eliminates
these larger micelle structures. Unfortunately, it’s harder to differentiate between the non-EV
structures that are similar in size to the EVs that have taken up the dye. The PKH dye should be
used with a determined protein concentration, and canonical EV markers can further aid in
confirming whether PKH positive puncta are true EVs or not.
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Figure 7. PKH Stained EVs from 293Ts Colocalize with CD81 and LAMP1, and Identify
S15Ch+ EVs (46). Concentrated EVs from WT 293T cells or PBS were dyed with PKH26 (PKH
Dye, green) at an initial dye concentration of 200nM or 400nM. A) Representative z-stack from
WT 293T EVs or PBS demonstrating co-localization of PKH Dye(green), CD81(red), and
LAMP1(Blue) or its respective secondary antibody control. The dye labelled EVs were imaged
and 3D reconstructions were used to identify dye positive EVs using the same spots masking
algorithm for both dye concentrations to determine their co-localization with CD81 and LAMP1.
B, C) Representative co-localization from a 200nM PKH dye image demonstrate relative colocalization. A total of three (D) and five (E) independent replicates were conducted for the
200nM and 400nM conditions, respectively. 10-15 images were taken per coverslip for each
condition for each replicate. The number of EVs identified per image ranged from ~200-780.
Concentrated S15Ch 293T EVs were either dyed with PKH67 (Dye) with an initial dye
concentration of 200nM or remained unstained. Both the undyed and dye labelled S15Ch EVs
were then imaged, and 3D reconstructions were used to generate a spots masking algorithm
around the dye positive (F) or S15Ch positive (G) EVs. F) The percent of Dye+ EVs, as
identified by its spots, demonstrate that the S15Ch could be reproducible found within the
concentrated EVs. G) The percent of S15Ch positive EVs, as identified by its spots algorithm,
show their co-localization with the dyed EVs (left) are undyed EVs (right). three independent
replicates were conducted. 10-15 images were taken per replicate. The number of identified Dye
EVs per image ranged, from ~1100-1500; number of S15Ch identified EVs per image ranged,
~350-600. All data shows the mean value among replicates, error bars show the standard error of
the mean.
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Before progressing to the analysis of EVs released under inflammatory conditions, we
wanted to also verify the accuracy of our microscopy techniques, specifically the binning settings
we chose for our images. Modern digital cameras have a charged coupled device photon
detector, which captures and stores image information in the form of localized electrical charge.
Each electrical charge signal corresponds with a different light intensity. Each one of these
signals is associated with a picture element, or a pixel, and each signal is read out quickly as an
intensity value for that specific location. These values become quickly digitized and form the
image we see on screen. Additionally, each pixel can be thought of as a well of electrons, and
when that well becomes filled, pixels lose their ability to accommodate any additional charge.
That charge can then be spread to neighboring pixels, which can give the impression of incorrect
values or allow neighboring pixels themselves to reach saturation. With all that in mind, binning
is the concept of combining charge from adjacent pixels. Binning ensure that Signal-to-noise
ratio is lower, and at higher binning photos are digitized faster. We wanted to confirm that our
binning setting of 2x2 doesn’t affect our picture resolution versus a binning of 1x1. The overall
trends we saw for our S15Ch+ puncta weren’t affected in a binning of 2x2 vs. a binning of 1x1,
as seen in Figure 8.
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Figure 8. S15Ch+ Puncta Colocalized with CD81 and LAMP1 from Bin 1x1 and Bin 2x2
Collected Fields (46). D) S15Ch co-localization distribution for S15Ch EVs stained with CD81
and LAMP1 from Bin 1x1 and Bin 2x2 collected fields. 12 images were taken per coverslip. All
data shows the mean value among replicates, error bars show the standard error of the mean.
With an established system in visualizing, quantifying, and analyzing EVs, we then
turned our sights into applying these methods to analyze EV populations under both normal and
inflammatory conditions. As mentioned earlier while discussing inflammation, NLRP3
inflammasome activation, driven by caspase-1, leads to a plethora of proteins being released
from cells, more so than when the inflammasome isn’t activated. We wished to analyze these EV
populations under normal conditions vs. conditions where the NLRP3 inflammasome was active.
Accepted modes of NLRP3 activation include priming cells with LPS for 4 hours, and then
following up with agonists such as ATP, anywhere from 30 minutes to 3 hours.
To confirm the inflammasome was truly activated upon our LPS/ATP treatments,
supernatant from differentiated THP-1 cells after 4 hours LPS/ 1 hour ATP treatments was
collected. Throughout the treatments, cells were observed microscopically to ensure cells
weren’t pyroptotic, and LDH assays done by other lab members have showed that these
treatment times don’t induce pyroptosis (Data not shown). Upon collection, supernatant was
spun down at 3000 x g for 10 minutes to eliminate any potential cell debris. Afterwards, that
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supernatant was collected and saved. An ELISA was run on that supernatant, looking for IL-1
levels that were quantifiably larger under LPS/ATP treatment vs. no treatment. IL-1 secretion
from the ELISA are shown in figure 9 below.

Figure 9. NLRP3 Inflammasome Activation Asserts Noticeable Increase in IL-1 Release.
Differentiated THP-1’s were either not treated, or treated with LPS for 4 hours followed by ATP
for 3 hours. Supernatant was collected from cells, and an IL-1ß ELISA was run on the
supernatant with two dilutions: 1:10 and 1:25.
With the confirmation that we indeed activate the inflammasome with our treatments, we
now can analyze EV released from these cells by staining them for various markers of our
choosing. Figure 10 below demonstrates an example of the type of analyzations we can conduct
with our approach. We see a substantially greater number of puncta under the 4 hours LPS/ 3
hours ATP treatment versus when we don’t treat the cells with priming and activating signals.
Additionally, one can appreciate that the distribution of markers is also altered under
inflammasome activation versus when the inflammasome is not active. It is these differences that
can be beneficial upon distinguishing EVs from normal versus pathological conditions. These
analyses can be done with a large variety of markers to gate on and other cargoes to stain for, and
future potential experiments are further described in Chapter Five.
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Figure 10. Tetraspanin CD81 and Cytokine IL-1 Gated Around Lectin PHAE Under Both
No Treatment Conditions vs. Inflammasome Activation. An average of 10-15 images were
taken for each condition. Left most graph indicates secondary only antibody control, middle
indicates no treatment (NT) and right most graph under LPS+ ATP treatment. Percent triple
positive, i.e. puncta gated around PHAE that were also positive for IL-1 and CD81, were
roughly 4 times larger under the inflammasome activating treatments compared to NT. A larger
percentage of released EVs were also positive for PHAE and CD81 under inflammasome
activation compared to NT.

CHAPTER FIVE
DISCUSSION AND FUTURE DIRECTIONS
Using quantitative fluorescent microscopy, we are able to navigate through different EV
populations, applying accepted notions in the field towards more novel and elusive approaches.
Our approach is straight-forward and allows for the heterogeneity of EV populations to more
clearly be defined, versus other approaches that either don’t encompass the heterogeneity, or
require far more advanced technology that is not always easily accessible. By building surfaces
around our proposed EVs and then confirming them by staining for various markers, we are able
to analyze thousands of EVs rather quickly. Additionally, we can analyze them in a cargospecific manner, and differences between populations carrying different cargos can be beneficial
in examining pathogenic EVs. Using other approaches to label EVs, such as with lectins and
PKH membrane dyes, further emphasizes the versatility EV-MAC can incorporate.
There are many exciting avenues to continue exploring with our EV-MAC categorizing
techniques. Of course, established EV markers such as tetraspanins and ESCRT proteins have
long been used in the field. We are very excited about the utilization of lectins for further
analyzation of carbohydrate enriched areas on EVs. A caveat to the approach using lectins, and
one that we fortunately caught early on, is that lectins recognize glycosylated regions on
carbohydrates, and antibodies we use to label certain markers or cargos are also glycosylated.
Hence, we ran into the problem that the lectins may have been recognizing antibody structures,
and thus some of our colocalization may not have been entirely accurate. To circumvent this
problem, we have ordered antibodies lacking the Fc portion of the antibody structure, which is
30
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the most glycosylated part of the antibody, in hopes that this issue would be somewhat more
controlled. Additionally, we will be optimizing our staining techniques, such that lectin staining
would take place prior to antibody staining. Lastly, we can use fluorescently conjugated proteins
that don’t require antibody staining to use for our lectin staining experiments. There is a lot of
potential with the lectin staining, and we are very excited about the prospect of categorizing a
diverse range of EVs from different cell types and environments and seeing how their
carbohydrate composition is altered. This can further give us insight as to the role these EVs
have in regard to cell-to-cell communication and fusion with target cells.
The membrane dye also carries potential for future experiments. We have shown that the
dye labels all of our S15Ch+ puncta, which we expect to be incorporated into various
membranes. Interestingly, only 50% of the dye puncta are positive for the S15Ch+ puncta. This
raises a few interesting questions. The quality of our S15Ch transfections will always vary, and
it’s difficult to conceive a widespread 100% effective transfection. It is possible that there was
some S15Ch signal present with dye puncta, however maybe not strong enough for our scope to
detect it, or more simply that our S15Ch as mentioned just wasn’t incorporated into all
membranes. We expect that most of the 50% of the dye that wasn’t positive for S15Ch+ are EVs,
with some dye-forming micelles which to the best of our abilities we simply aren’t able to
exclude. While it doesn’t give us the carbohydrate-defining distributions our lectin staining
provides, it does stain proposed EVs well, and allows us to stain for other cargos or markers
concurrently without having to worry about the problems we ran into with the lectins.
As mentioned, of specific interest to me is utilizing EV-MAC for studying inflammation.
A multitude of proteins are released from cells upon inflammatory induction, and many bypass
the conventional protein secretion pathway, thus taking other routes to be released from host
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cells. Using our EV labeling approaches, we can stain for various markers as long as we have the
available antibodies to them. We can stain for different inflammasome-related components and
see if more are released under inflammatory induction, and how the distribution of markers is
altered upon such inductions as well. I’ve demonstrated the type of experiments we would
conduct in Figure 10. As stated, we wouldn’t be able to repeat this experiment again while using
a lectin and staining for cargos using antibodies without further protocol optimization. However,
it stands to reason based on the trend we saw and what’s been shown in the literature that EV
compositions should be altered upon inflammatory induction, even when just considering the
proteins released under inflammasome activated conditions versus normal.
There were many additional experiments that, due to unforeseen circumstances, couldn’t
be completed. Referring back to using EV-MAC to study EVs released under normal versus
inflammasome activated conditions, I would be curious to stain for other proteins that have been
shown to be released extracellularly and see if they are associated with EVs. Such proteins would
be NLRP3, Caspase-1, and ASC. ASC in particular holds the most interest to us.
As described in Chapter Two, ASC forms these defined, speck like puncta within cells
under inflammasome activation, and these specks have also been found extracellularly. There are
many questions we would like to ask regarding the functions of this extracellular ASC, as it has
been shown to exhibit prion-like qualities. We would answer these questions using an ASC-GFP
THP-1 cell line, where ASC would be fluorescently tagged with GFP. By treating with our
NLRP3 inflammasome activators LPS + ATP, we would be able to visualize green ASC puncta
within the cell, versus a diffuse green in cells that weren’t treated with LPS + ATP. Our first
question would be if extracellular ASC is released from cells in the context of EVs. We would
use EV-MAC to answer this. We would collect supernatant from ASC-GFP treated cells, spin
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them down onto coverslips, and stain for various EV markers, stain for lectins, or use our
membrane dye. We can gate around our GFP+ puncta, and see colocalization patterns with our
other markers, or we can gate around our EV markers and see how much ASC colocalizes with
them. With either method, we would be able to definitely show that ASC is or isn’t released in
the context of EVs. Regardless of whether it is or isn’t released with EVs, we can still explore
the prion like qualities of ASC. We can add concentrated supernatant of ASC-GFP to cells that
express ASC-mCherry. One would expect that exogenous ASC-GFP wouldn’t be able to degrade
upon entering the host cell, which begs the question: What does it do upon endocytosis? Would
we see ASC-GFP interacting with endogenous ASC-mCherry? What happens to exogenous ASC
upon uptake? Our lab has shown that when -synuclein is taken up by target cells and sorted
within endosomes, we see vesicular rupture as evident by gal-3 colocalization. It would be
fascinating if we saw something similar with ASC taken up and using an endogenously
expressed gal-3-mCherry to confirm vesicular rupture. Our approach for analyzing EVs can
assist in answering and elucidating many previously discussed observations, and I look forward
to seeing where these experiments unfold with future students.
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